LIAN(Delisted)
LianBioยทNASDAQ
--
--(--)
Key Stats
0.0000DAY`S RANGE0.0000
0.000052 WK RANGE0.0000
0.0000
0.0000
--
--
--
--
--
--
--
--
--
--
--
--
--
--
0.0000
0.0000
0.0000
0.0000
About LIAN
Lianbio
A biotech company that develops therapies to treat cardiovascular, oncology, respiratory, ophthalmology, and inflammatory disease
--
07/17/2019
11/01/2021
NASDAQ Stock Exchange
163
12-31
Depository Receipts (Ordinary Shares)
103 Carnegie Center Drive, Suite 215, Princeton, NJ 08540
--
LianBio was incorporated in the Cayman Islands on July 17, 2019. The company is a global, science-oriented biopharmaceutical company dedicated to the development and commercialization of innovative medicines for patients with unmet medical needs, initially focusing on licensed assets in Greater China and other Asian markets. The company has purposefully designed their organization to successfully execute their vision by identifying, sourcing, developing and commercializing product candidates and partnering with highly innovative biopharmaceutical companies around the world. The company is building an international infrastructure, positioning themselves as partners of choice and providing a platform to provide access to their target markets.
Company Financials
EPS
LIAN has released its 2023 Q3 earnings. EPS was reported at -0.22, versus the expected -0.3, beating expectations. The chart below visualizes how LIAN has performed over recent quarters, highlighting trends in earnings surprises.
Forecast
Wall Street Opinions
Price Target
Volume Profile
Trade Flow Insight
Seasonals
Community Forum
Loading...
Related News
No articles available
Related Symbols
No Data
You can ask Aime
No Data
